DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 88.0% from a year ago
Cash & equivalents stood at $4.87M at the end of Q1 FY2026, up 88.0% from a year earlier and down 68.9% from the prior quarter. Over 3 fiscal years it compounded at +49.0% a year.
Context
- Cash & equivalents amounted to 9.2% of total assets at the end of Q1 FY2026, up 2.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +88.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 15.65M USD
- Year-over-year change
- +417.3%
- 4-year CAGR
- +35.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.65M | +417.3% |
| FY2024 | 2024-12-31 | 3.03M | -33.4% |
| FY2023 | 2023-12-31 | 4.54M | -3.9% |
| FY2022 | 2022-12-31 | 4.73M | +0.4% |
| FY2021 | 2021-12-31 | 4.71M | — |
Cash & Equivalents vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 cash & equivalents of $4.87M is the lowest of the 7 companies compared; the peer median is $180.71M.
- Its year-over-year change of +88.0% is the 2nd highest of 7, against a peer median of +23.5%.
- Cash & equivalents amounts to 9.2% of total assets for DMAC, versus a peer median of 46.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M | -6.1% | +89.8% | 60.8% |
| Jun 2026 | $201.53M | +42.7% | -2.0% | 17.4% | |
| Mar 2026 | $198.77M | -32.5% | +23.7% | 47.4% | |
| Mar 2026 | $162.64M | +43.5% | +26.9% | 44.9% | |
| Mar 2026 | $101.9M | +4.2% | -39.5% | 34.8% | |
| Mar 2026 | $37.37M | +89.0% | +300.4% | 58.0% | |
| Mar 2026 | $4.87M | +88.0% | +49.0% | 9.2% | |
| Peer median (excluding DMAC) | $180.71M | +23.5% | +25.3% | 46.1% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.